Segmentation of consumers includes when someone in the household started taking GLP-1
The evidence base now supports both short-term weight loss and long-term metabolic improvement
How did we find a way to show Serenas improved blood sugar and overall health without turning the ad into a medical explainer
Other GLP-1R, GIPR, and glucagon receptor (GCGR) poly-agonists are in development and have been tested in phase 1 and phase 2 clinical trials, including GLP-1R/GCGR agonists, GLP-1R/GLP-2R agonists, and triple GLP-1R/GIPR/GCGR agonists (abstracts presented at the American Diabetes Association Annual Meeting in June, 2022 and (7))
However, with the convenience-focused modern era, people are consuming more carbohydrate-heavy foods, which has led to weight gain and increased reliance on weight-loss medications
FuturHealth FuturHealth earns a 4.7/5.0 on our weighted scoring system